TNIK
-
Business & Markets · Enterprise Insilico Medicine Reports Positive Phase IIa Results For a First-in-Class Drug Treatment For Idiopathic Pulmonary Fibrosis Designed by Generative AI
Insider Brief Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial. ISM001-055 is a novel drug designed in-house using generative AI to target TNIK… -
Business & Markets · Enterprise
AI-designed TNIK Inhibitors Could Treat a Range of Aging-Related Diseases, From Fibrosis to Alzheimer’s.
The AI economy, every weekday morning
The daily briefing plus the weekly Scale-ups to watch edition. Free, no spam, unsubscribe any time.